These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19048251)

  • 1. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
    Ishida T; Ishii T; Inagaki A; Yano H; Kusumoto S; Ri M; Komatsu H; Iida S; Inagaki H; Ueda R
    Leukemia; 2006 Dec; 20(12):2162-8. PubMed ID: 17039235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
    Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
    Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
    Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
    Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
    Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
    Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
    Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.
    Han T; Abdel-Motal UM; Chang DK; Sui J; Muvaffak A; Campbell J; Zhu Q; Kupper TS; Marasco WA
    PLoS One; 2012; 7(9):e44455. PubMed ID: 22973452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
    Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
    Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
    Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
    J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
    Ishida T; Ishii T; Inagaki A; Yano H; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Res; 2006 Jun; 66(11):5716-22. PubMed ID: 16740709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-CCR4 mAb and regulatory T cells].
    Kurose K; Ohue Y; Oka M
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
    Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR4 as a novel molecular target for immunotherapy of cancer.
    Ishida T; Ueda R
    Cancer Sci; 2006 Nov; 97(11):1139-46. PubMed ID: 16952304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
    Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
    Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
    Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
    Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ; Snyder KM; Khaw M; Hullsiek R; Davis ZB; Matson AW; Shirinbak S; Hancock B; Bjordahl R; Hosking M; Miller JS; Valamehr B; Wu J; Walcheck B
    Front Immunol; 2024; 15():1407567. PubMed ID: 39100677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.